

www.ascept-paganz.com



AUSTRALASIAN SOCIETY OF CLINICAL AND EXPERIMENTAL
PHARMACOLOGISTS AND TOXICOLOGISTS



**100% PURE
NEW ZEALAND**
newzealand.com

Queenstown, New Zealand
25-29 November 2019

Joint scientific meeting

Shared horizons: Optimising drug response to improve patient outcomes
#ASCEPTPAGANZ2019

**Poster
Program**

Wednesday 27 November 2019, 10:30 – 11:10 and 13:15 – 14:10**Clinical Pharmacology**

437	Pharmaceutical Benefits Scheme (PBS) subsidised opioid medicines Dr Christina Abdel Shaheed, Institute For Musculoskeletal Health, The University of Sydney, Australia
438	Health consumers' perspectives of Saudi pharmacists' roles in cardiovascular disease prevention Mr Hadi Almansour, The University of Sydney, Australia
439	The effect of immunosuppressant prescribing patterns on patient outcomes in elderly Australasian kidney transplant recipients Ms Amelia Cossart, The University of Queensland, Australia
440	Intensive rheumatoid arthritis therapy using a methotrexate loading dose schedule Mrs Dala Daraghmeh, University of South Australia, Australia
441	Selection of suitable probe substrates to determine drug-metabolising enzyme activity in extracellular vesicles Ms Alia Fahmy, Flinders University, Australia
442	Chronic polypharmacy and the Drug Burden Index (DBI) effects muscle function and structure in aged mice: Association with gut microbiome Ms Gizem Gemikonakli, Kolling Institute of Medical Research; The University of Sydney, Australia
443	NSW Cannabis Medicines Advisory Service (CMAS) methodology and evolution Ms Myfanwy Graham, NSW CMAS, Australia
444	Evaluation of fixed versus weight-based dosing regimens of intravenous vancomycin in patients receiving high-flux haemodialysis Dr Katrina Hui, Monash University, Australia
445	Evaluation of data sharing statements within the top ten general and internal medical journals Ms Navkiran Kaur, Flinders University, Australia
446	Population pharmacokinetic models of tacrolimus in adult transplant recipients: A systematic review Ms Ranita Kirubakaran, University of New South Wales, Australia
447	External evaluation of published population pharmacokinetic models of tacrolimus in adult heart transplant recipients Ms Ranita Kirubakaran, University of New South Wales, Australia
448	Population pharmacodynamic modeling of sevoflurane as a bioequivalence test Dr Seong-heon Lee, Chonnam National University Medical School, South Korea
449	Prescribing practices of secondary stroke prevention medications at discharge from a large tertiary hospital Miss Dorsa Maher, University of South Australia, Australia
450	Medication adherence in gout: Identifying high-risk patient groups in an Australian clinical setting Mr Chi Mao, University of New South Wales, Australia
451	Unbound mycophenolic acid exposure is significantly higher prior to kidney transplantation, stabilizing over the first 2 post-transplant weeks Dr David Metz, The University of Melbourne, Australia
452	Validity and reliability of clinical resources on adverse effects of medicines: Drug-induced liver injury Mrs Marie-claire Morahan, Canterbury District Health Board, New Zealand
453	Development of an optimal sampling schedule for neonates and infants undergoing propofol infusions Mr James Morse, University of Auckland, New Zealand
454	Simultaneous quantification of four beta-Lactams in human plasma for therapeutic drug monitoring Miss Janni Mortensen, University of Copenhagen, Denmark
455	Development of a novel LC-MS method to measure CYP2D6 activity in extracellular vesicles Ms Reham Mounzer, Flinders University, Australia
456	Optimal design for the estimation of cefuroxime population parameters in the paediatric intensive care setting Mr Conor O'Hanlon, University of Auckland, New Zealand
457	Opioid exposure and cancer outcome Assoc Prof Marie-Odile Parat, The University of Queensland, Australia
458	Accuracy of documented administration times for intravenous antimicrobial drugs Ms Steph Roydhouse, University of New South Wales; St Vincent's Hospital, Sydney, Australia
459	Real-world efficacy and safety outcomes of imatinib treatment in patients with Chronic Myeloid Leukemia: An Australian experience Miss Josephine Touma, The University of Sydney, Australia
460	Proteomic analysis of drug metabolising enzymes in extracellular vesicles Dr Madel� Van Dyk, Flinders University, Australia
461	Diabetic complications prevalence among patients treated with oral hypoglycemic agents and/or insulin at Suva Diabetic Hub from 2015 – 2017 Mr Napolioni Vulakouvaki, Fiji National University, Fiji
462	Barriers and facilitators to user acceptance of a pilot therapeutic drug monitoring advisory service for vancomycin Miss Rachel Yager, University of New South Wales, Australia

Wednesday 27 November 2019, 10:30 – 11:10 and 13:15 – 14:10**Clinical Pharmacology Trainee**

463	Single-centre retrospective audit on the use of tapentadol and discharge communication Dr Arushi Madan, Royal Brisbane & Women's Hospital, Australia
464	Monitoring for phenytoin toxicity in patients with hypoalbuminemia Dr Arushi Madan, Royal Brisbane & Women's Hospital, Australia

Wednesday 27 November 2019, 10:30 – 11:10 and 13:15 – 14:10**Drug Discovery**

476	Development of a cell-based assay for screening of P2X1-purinoreceptor antagonists for use in male contraception Mr Felix Bennetts, Monash University, Australia
477	Developing Cannabinoids to target T-type calcium channels involved in epilepsy Dr Christopher Bladen, Macquarie University, Australia
478	Orai channel alterations as a consequence of differentiation in a human neural progenitor cell line Ms Silke Chalmers, The University of Queensland, Australia
479	Investigating the role of the calcium-sensing receptor in airway contraction using mouse precision cut lung slices Miss Jiayin Diao, Monash University, Australia
480	Using untargeted metabolomics to discover the killing mechanism of Ceftazidime-avibactam against multidrug resistant <i>K. pneumonia</i> Ms Drishti Ghelani, The University of Melbourne, Australia
481	Dissecting mechanisms of fenestration dynamics in liver sinusoidal endothelial cells Mr Christopher Florian Holte, University of Tromsø, Norway
482	Live cell imaging: An assessment tool for breast cancer cell death Ms Trinh Hua, The University of Queensland, Australia
483	Nanomedicine based delivery of metformin and nicotinamide mononucleotide (NMN) to single cell types of the liver via oral administration Dr Nicholas Hunt, The University of Sydney, Australia
484	Unravelling signalling mechanism of peptide mimetic at the relaxin receptor RXFP1 in human cardiovascular cells Dr Martina Kocan, Florey Institute; Melbourne University, Australia
485	Oxidative stress and calcium signalling in breast cancer and human fibroblast cell co-cultures Ms Karman Lee, The University of Queensland, Australia
486	Interleukin-18: A novel target for drug discovery to treat hypertension? Dr Maggie Lieu, Clarivate Analytics, Australia
487	Assessment of Ca²⁺ channels and pumps in brain-seeking breast cancer cell lines Mr Darren Lim, The University of Queensland, Australia
488	Expression of Wnt signalling components and cytotoxicity of Wnt inhibitors in colorectal cancer HCT-15 and HCT116 cells Dr Johnson Liu, University of New South Wales, Australia
489	Developing a systematic efficient method to determine synergistic 3 herb combinations in the search for osteoarthritis treatments Dr Mitchell Low, Western Sydney University, Australia
490	Development of a safe and effective painkiller from the spider venom peptide Pn3a Mr Alexander Mueller, The University of Queensland, Australia
491	AG-OX, a potent inhibitor of interactions between S100A9 and RAGE/TLR4, selectively inhibits S100A9-positive triple-negative breast cancer Mr Kyung Yul Oh, Sungkyunkwan University, South Korea
492	Biased agonism at chemokine receptors: critical role for the chemokine N-terminal region Assoc Prof Martin Stone, Monash University, Australia
493	Development of a luciferase complementation method to investigate extracellular CXCR4 conformational changes Dr Carl White, University of Nottingham, UK; University of Western Australia, Australia
494	A traditional anti-inflammatory from Tasmania and Southern NZ: Mutton Bird Oil (MBO) Prof Michael Whitehouse, Griffith University, Australia

Wednesday 27 November 2019, 10:30 – 11:10 and 13:15 – 14:10**Pharmacogenomics**

517	CYP2D6 genotype distribution in Aboriginal and non-Aboriginal Australians Dr Daniel Barratt, University of Adelaide, Australia
518	Prediction of pharmacokinetics in lornoxicam by CYP2C9 genetic polymorphism: From in vitro to clinical studies Mr Chang-Keun Cho, Sungkyunkwan University, South Korea
519	Estimating concentration of venlafaxine and its metabolite in case of enzyme polymorphism and renal impairment Mr Chang-Keun Cho, Sungkyunkwan University, South Korea
520	Simulation of metoclopramide pharmacokinetic model according to CYP2D6 genotypes in adults and pediatric patients Ms Shin Hyo Bin, Sungkyunkwan University, South Korea
521	Prediction of flurbiprofen pharmacokinetics from using in vitro metabolism data in relation to CYP2C9 genetic polymorphism Ms Shin Hyo Bin, Sungkyunkwan University, South Korea
522	Should we be investigating inter-individual differences in biliary excretion of 5-Fluorouracil (5-FU) as a risk factor for 5-FU toxicity? Dr Soo Hee Jeong, University of Auckland, New Zealand
523	The effects of CYP2C19 genetic polymorphism on the pharmacokinetics of omeprazole using physiology and physicochemistry based pharmacokinetic predictions Mr Eui-hyun Jung, Sungkyunkwan University, South Korea
524	Physiology and physicochemistry based pharmacokinetic predictions: Effect of CYP2C9 genetic polymorphism on candesartan pharmacokinetics Mr Eui-hyun Jung, Sungkyunkwan University, South Korea
525	Prediction of propranolol pharmacokinetics changes according to the variation in genetic and non-genetic factors Mr Choong-min Lee, Sungkyunkwan University, South Korea
526	Prediction of metoprolol pharmacokinetics changes according to the variation in genetic and non-genetic factors Mr Choong-min Lee, Sungkyunkwan University, South Korea
527	Attitudes of healthy volunteers in phase I clinical trials to genetic testing Mr Sebastian Levesque, The University of Adelaide, Australia
528	Pharmacogenetic variants and psychological factors do not explain self-reported antidepressant side effects Dr Simran Maggo, University of Otago, Christchurch, New Zealand
529	The optimization of voriconazole dosing related to CYP2C19 major alleles in healthy Asian Mr Kyung Yul Oh, Sungkyunkwan University, South Korea
530	A QPCR-block assay for the detection of inter-individual differences in melphalan-induced DNA damage Miss Maia van Kan, University of Auckland, New Zealand
531	PNG HIV/AIDS patients have unique genetics Miss Helena Van Schalkwyk, University of Adelaide, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Cardiovascular**

400	Naturally occurring polymorphisms in cardiac bitter taste receptors (T2Rs) dramatically alter receptor function Mr Conor Bloxham, The University of Queensland, Australia
401	The trends and opinions of Australian clinicians on the use of antihyperglycemic agents in heart failure patients Mrs Gina Chowdhury, University of New South Wales, Australia
402	Impact of diabetes on the murine cardiac cellular landscape and systemic leukocyte proportions Mr Charles Cohen, Baker Heart and Diabetes Institute, Australia
403	Defining the characteristics of an alternate mouse model of type-2 diabetes (T2D)-induced cardiomyopathy Dr Miles De Blasio, Baker Heart and Diabetes Institute, Australia
404	Diabetes impairs the contribution of nitric oxide (NO[•]) but not nitroxyl (HNO) to endothelium dependent relaxation in rat carotid arteries Miss Jasmin Li, Baker Heart and Diabetes Institute, Australia
405	Pharmacological activity of perhexiline enantiomers in an isoprenaline model of myocardial damage Dr John Licari, University of Adelaide, Australia
406	Adiponectin receptor gene therapy as a treatment for diabetic cardiomyopathy in mice Mr Michael Mah, Baker Heart and Diabetes Institute, Australia
407	The effects of cannabidiol on the contractions of rat isolated mesenteric arteries and other muscle tissues Ms Amna Mazeah, The University of Melbourne, Australia
408	Gene delivery targeting cardiac O-GlcNAc improves mitochondrial function in a model of diabetic cardiomyopathy Dr Darnel Prakoso, Baker Heart and Diabetes Institute, Australia
409	Reduced adenosine A2B receptor protein expression in adult rat primary cardiac myofibroblasts Assoc Prof Roselyn Rose'meyer, Griffith University, Australia
410	Targeting the NLRP3 inflammasome as a novel approach to treat pulmonary hypertension Mrs Tara Scott, Monash University, Australia
411	Investigating the impact of high glucose on adiponectin signalling in human iPSC-derived cardiomyocytes Ms Abhipree Sharma, Baker Heart and Diabetes Institute, Australia
412	Investigating the mechanisms of the inhibitory effects of relaxin on the NLRP3 inflammasome in myofibroblasts Mr Felipe Tapia, Monash University, Australia
413	The mitochondria-targeted methylglyoxal sequestering compound, MitoGamide, is cardioprotective in the diabetic heart Dr Mitchel Tate, Baker Heart and Diabetes Institute, Australia
414	Nitroxyl-based therapies to overcome nitric oxide resistance in the diabetic heart and vasculature Ms Anida Velagic, Baker Heart and Diabetes Institute, Australia
415	Post-stroke cognitive impairment is exacerbated in hypertensive mice Mr David Wong Zhang, La Trobe University, Australia
416	The M2 macrophage-derived chemokine, CCL18 is elevated in hypertension and promotes vascular fibrosis Miss Mingyu Zhu, Monash University, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Urogenital and Gastrointestinal**

417	The role of prostaglandin E2 in mediating urinary bladder contractions Miss Zane Stromberga, Bond University, Australia
418	Purinergic P2X7 receptor inhibition protects urothelial cells from acrolein-induced cell death, which is independent of oxidative stress Miss Zhinoos Taidi, University of New South Wales, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Toxicology**

419	Preliminary validation and application of a LCMS/MS method to quantify plasma efavirenz and metabolites in Papua New Guinea HIV/AIDS patients Miss Natalia Bordin Andriqueti, University of Adelaide, Australia
420	Traditional Chinese herbs: The toxicity of polyherbacy in in vitro models of at-risk organ structures Ms Susan Britza, University of Adelaide, Australia
421	Assessing quantum mechanical chemical descriptors for modelling toxicological outcomes Mr Davy Guan, The University of Sydney, Australia
422	Optimising the methylthiol reaction model for predicting in vitro Direct Peptide Reactivity Assay results Mr Davy Guan, The University of Sydney, Australia
423	Hybrid toxicogenomic augmented structure activity relationships for chemical carcinogenicity prediction Mr Kerry Heffernan, The University of Sydney, Australia
424	The in vitro neurotoxicity of Indian cobra (Naja naja) venom: Efficacy of antivenom Mr Tam Huynh, Monash University, Australia
425	Multitask deep learning for metabolism-aware strain-specific assessment of Ames mutagenicity Mr Raymond Lui, The University of Sydney, Australia
426	The quality and potential toxicity of herbal medicines assessed via the two pronged approach of Metabolomics and Next Generation Sequencing Dr Ian Musgrave, University of Adelaide, Australia
427	Perhexiline limits both doxorubicin cardiotoxicity and cancer growth in a human osteosarcoma xenograft model Prof Benedetta Sallustio, The Queen Elizabeth Hospital, Australia
428	Developing techniques to isolate and characterise individual Russell's viper venom peptides and proteins Ms Rachael Thomas, University of South Australia, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Education**

429	Are there any relationships between student demographics or their lecture attendance and academic outcomes? Dr Sheila Doggrell, Queensland University of Technology, Australia
430	Designing and delivering a Biology Bridging unit to 1st year Pharmacy Dr Betty Exintaris, Monash Institute of Pharmaceutical Sciences, Australia
431	Development of scientific writing and referencing skills in pharmacology students Dr Lynette Fernandes, University of Western Australia, Australia
432	The IUPHAR Pharmacology Education Project: Opportunities and challenges Assoc Prof Clare Guilding, Newcastle University Medicine Malaysia, Malaysia
433	Evaluating Multiple Choice Question (MCQ)-based summative assessments in Pharmacy Education: An integrative review Dr Nilushi Karunaratne, Monash University, Australia
434	Medication reviews and geriatric medicine home visits Dr PK Loh, Edith Cowan University, Australia
435	Spaced education improves student performance in medical education Dr Slade Matthews, The University of Sydney, Australia
436	Conventional and complementary medicine health care practitioners' perspectives on interprofessional communication: A qualitative rapid review Miss Janet Nguyen, The University of Sydney, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Drug Disposition and Response**

465	The role of UGT enzymes in cytotoxic drug resistance in breast cancer Mr Radwan Ansaar, Flinders University, Australia
466	Impact of phenotype and pregnancy related induction of CYP2D6 expression on exposure to codeine and morphine following oral codeine dosing Miss Sarah Badaoui, Flinders University, Australia
467	Use of PBPK modelling to identify covariates driving variability in sunitinib exposure and predict optimal dosing Ms Bronwyn Beelders, Flinders University, Australia
468	Clinical study to assess the magnitude, time-course and variability of Human CYP3A4 induction by rifampicin in a healthy volunteer cohort Ms Asha Kapetas, Flinders University, Australia
469	Serum-derived small extracellular vesicles as diagnostic biomarkers for non-alcoholic fatty liver disease Ms Lauren Newman, Flinders University, Australia
470	Isothiocyanates from cruciferous vegetables and breast cancer: A systematic review Dr Suong Ngo, The University of Adelaide, Australia
471	Pharmacokinetics of Treosulfan in paediatric patients Mr Sebastian Rosser, The Children's Hospital, Westmead, Australia
472	Deconvolution of apparent CYP2D6 induction by rifampicin using an extracellular vesicle derived biomarkers Assoc Prof Andrew Rowland, Flinders University, Australia
473	Characteristics of extracellular vesicles secreted by HepaRG following removal of media component Mr Warit Ruanglertboon, Flinders University, Australia
474	The effect of chronic polypharmacy, monotherapy and deprescribing on the kidneys of aged mice Ms Ji Sang Ryu, Kolling Institute of Medical Research; The University of Sydney, Australia
475	Sulfasalazine: A controversial pro-drug to treat rheumatic diseases Prof Michael Whitehouse, Griffith University, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Neuro- and Behavioural Pharmacology**

495	Oxytocin-vasopressin ligand-receptor bias for Gq signalling: Man and mouse Mr Kiyam Afzali, The University of Sydney, Australia
496	Targeting spinal A1 adenosine receptors with allosteric modulators to reduce pain signalling Ms India Cowie-kent, Monash University, Australia
497	The orexins exhibit distinct pharmacological profiles at orexin receptor 2 Miss Natasha Dale, Harry Perkins Institute of Medical Research, Australia
498	The role of caveolae in osmotic pressure-induced glioblastoma invasiveness Assoc Prof Marie-Odile Parat, The University of Queensland, Australia
499	Brain activity in response to z-drugs: Role for GABAA γ1 and γ3 subunits Mr Grant Richter, The University of Sydney, Australia
500	Investigation of the specificity of cannabidiol signalling Miss Shivani Sachdev, Macquarie University, Australia
501	Rational replicons: A viral replication model for memory engrams Mr Tim Shaw, The Peter Doherty Institute, Australia
502	Divergent pathways mediate effects of a 5-HT1A receptor agonist on social interaction, grooming and aggression in mice: Involvement of oxytocin Mr Oliver Tan, The University of Sydney, Australia
503	Assessing assay bias in fluorescence-based high throughput screening of voltage-gated sodium channels Mr Bryan Tay, The University of Queensland, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Pharmacoepidemiology**

504	A prognostic model for advanced lung cancer patients treated with atezolizumab Dr Ashley Hopkins, Flinders University, Australia
505	Risk of falling and the use of falls risk medications in residents of aged care services Dr Jenni Ilomaki, Monash University, Australia
506	Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review Miss Marissa Sakiris, The University of Sydney, Australia
507	Caregivers' experiences of medication management advice for people with dementia at hospital discharge: A qualitative study Dr Mouna Sawan, The University of Sydney, Australia
508	Efficacy and safety of tapentadol immediate release for acute pain: A systematic review and meta-analysis Miss Xinyi Wang, The University of Sydney, Australia

Thursday 28 November 2019, 10:40 – 11:10 and 13:15 – 14:10**Inflammation/Respiratory**

509	Viral infection exacerbates cigarette smoke-induced endothelial dysfunction in the mouse thoracic aorta Mr Kurt Brassington, RMIT University, Australia
510	Effects of prolonged exposure to paracetamol on late gestation rat placenta Miss Yifan Huang, The University of Melbourne, Australia
511	TLR4-dependent and -independent immune activation by cancer cell lysates Assoc Prof Marie-Odile Parat, The University of Queensland, Australia
512	Comparison of two mice models of non-alcoholic steatohepatitis Ms Cheng Peng, Baker Heart and Diabetes Institute, Australia
513	Glycolysis modulates NADPH oxidase 2 activity through the pentose phosphate pathway and Type I interferon-β Assoc Prof Stavros Selemidis, RMIT University, Australia
514	Living fast and dying young: Guanine oxidation and mitochondrial genomic GC content as regulatory factors Mr Tim Shaw, The Peter Doherty Institute, Australia
516	Therapeutic targeting of endosome and mitochondrial ROS protects mice from influenza infection Dr Eunice To, RMIT University, Australia